Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Guru Sonpavde MD

Guru P. Sonpavde MD

Genitourinary Oncology Director, Christopher K. Glanz Chair for Bladder Cancer Research, Assistant Director Phase I Clinical Research Unit, AdventHealth Cancer Institute, Orlando, Florida

Dr. Guru Sonpavde, MD, is the Genitourinary Oncology Director at the AdventHealth Cancer Institute and the Christopher K. Glanz Chair for Bladder Cancer Research. He completed his fellowship in medical oncology and hematology at Indiana University. He leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to treat urological cancers, particularly bladder cancer. He is the national or international principal investigator on multiple clinical trials for bladder cancer. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Cancers Steering Committee.

Disclosures

Dr. Sonpavde reports the following:

  • Advisory Board: BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals, Lucence Health, IMV

  • Research Support: Sanofi (iaward), Astrazeneca, Gilead, Helsinn, Lucence, Predicine, BMS, EMD Serono, Jazz Therapeutics, Genecentric, Kure it, NCI (R21)

  • Steering committee of studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and Astrazeneca, EMD Serono, Debiopharm (paid)
  • Data safety monitoring committee: Mereo
  • Employment: Spouse employed by Myriad
  • Writing/Editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence
  • Speaking fees: Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Cancer Network, Masters Lecture Series (MLS)

Recent Contributions to PracticeUpdate:

  1. Durvalumab for Patients With Metastatic Urothelial Carcinoma and Prior Chemotherapy
  2. ASCO GU 2021: Recommendations From Dr. Guru Sonpavde
  3. Plasma ctDNA Is a Tumor Tissue Surrogate and Enables Clinical-Genomic Stratification of Metastatic Bladder Cancer
  4. 2020 Top Stories in Bladder Cancer: Switch-Maintenance Avelumab Following First-Line Platinum-Based Chemotherapy—A New Paradigm in Advanced Urothelial Carcinoma
  5. Neoadjuvant Gemcitabine–Cisplatin Plus Radical Cystectomy–Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer
  6. Pembrolizumab Plus Acalabrutinib for Platinum-Resistant Metastatic Urothelial Carcinoma
  7. Preoperative Ipilimumab Plus Nivolumab in Locoregionally Advanced Urothelial Cancer
  8. Dr. Guru Sonpavde on the Results of the EV-201 Trial in the Cisplatin-Ineligible Post–PD-1/PD-L1 Inhibitor Cohort
  9. Neoadjuvant PD-L1 Plus CTLA-4 Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
  10. Upper Tract Urothelial Cell Carcinoma: Part 1

Elsewhere

Most Read This Week

Recently Updated